330 related articles for article (PubMed ID: 25483702)
1. Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.
Zhao G; Miao Y; Guo Y; Qiu H; Sun S; Kou Z; Yu H; Li J; Chen Y; Jiang S; Du L; Zhou Y
Hum Vaccin Immunother; 2014; 10(12):3649-58. PubMed ID: 25483702
[TBL] [Abstract][Full Text] [Related]
2. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
3. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
[TBL] [Abstract][Full Text] [Related]
4. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
5. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
6. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
7. Presenting Influenza A M2e Antigen on Recombinant Spores of Bacillus subtilis.
Łęga T; Weiher P; Obuchowski M; Nidzworski D
PLoS One; 2016; 11(11):e0167225. PubMed ID: 27902762
[TBL] [Abstract][Full Text] [Related]
8. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
[TBL] [Abstract][Full Text] [Related]
9. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
10. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.
Ni Y; Guo J; Turner D; Tizard I
Vaccine; 2017 Dec; 35(50):7026-7032. PubMed ID: 29102171
[TBL] [Abstract][Full Text] [Related]
12. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
13. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.
Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonossoff GP; Ravin NV
Bioengineered; 2016; 7(1):28-32. PubMed ID: 26710263
[TBL] [Abstract][Full Text] [Related]
14. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
15. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
16. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
17. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
18. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.
Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG
Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564
[TBL] [Abstract][Full Text] [Related]
20. Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
Ma D; Tian S; Qin Q; Yu Y; Jiao J; Xiong X; Guo Y; Zhang X; Ouyang X
Vaccine; 2023 Jul; 41(30):4402-4413. PubMed ID: 37308364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]